Actualización de medicamentos asociados a necrosis avascular de los maxilares. Perspectiva y revisión de literatura

L definición más aplicada de la osteonecrosis maxilar asociada a medicamentos (OMAM) es la original propuesta por la Asociación Americana de Cirujanos Maxilofaciales en el año 2014, ésta se basa en la presencia de todo lo siguiente: tratamiento previo o actual con bifosfonatos (BF) o denosumab o terapia antiangiogénica; una área de hueso expuesto necrótico en la Actualización de medicamentos asociados a necrosis avascular de los maxilares. Perspectiva y revisión de literatura.

• Publication year

  2020

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.35366/95113
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Methotrexate-related lymphoproliferative disorder arising in the gingiva of a patient with rheumatoid arthritis.

  2015cited by this paper
• Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus

  2015cited by this paper
• Drug induced osteonecrosis of the jaw.

  2015cited by this paper
• Bisphosphonates’ antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay

  2014cited by this paper
• Bisphosphonate-associated osteonecrosis of jaw reoccurrence after methotrexate therapy: a case report.

  2014cited by this paper
• Microsurgical Reconstruction After Bisphosphonate-Related Osteonecrosis of the Jaw: Our Experience With Fibula Free Flap

  2014cited by this paper
• Medication-Related Osteonecrosis of the Jaw—2014 Update

  2014cited by this paper
• Osteonecrosis of the jaw related to everolimus: a case report.

  2013cited by this paper
• Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report?

  2013cited by this paper
• Metastatic cancer identified in osteonecrosis specimens of the jaws in patients receiving intravenous bisphosphonate medications.

  2013cited by this paper
• Growth Factors , Cytokines , and Cell Cycle Molecules Methotrexate Chemotherapy Promotes Osteoclast Formation in the Long Bone of Rats via Increased Pro-Inflammatory Cytokines and Enhanced NF-B Activation

  2012cited by this paper
• Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

  2012cited by this paper
• Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients

  2012cited by this paper
• Biologics‐Based Therapy for the Treatment of Rheumatoid Arthritis

  2012cited by this paper
• Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.

  2012cited by this paper
• Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat

  2011cited by this paper
• Denosumab: an update.

  2011cited by this paper
• Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

  2010cited by this paper
• The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws.

  2009cited by this paper
• The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data.

  2009cited by this paper
• Osteonecrosis of the jaw related to bevacizumab.

  2008cited by this paper
• Inhibition of oral mucosal cell wound healing by bisphosphonates.

  2008cited by this paper
• Denosumab: an investigational drug for the management of postmenopausal osteoporosis

  2008cited by this paper
• Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.

  2008cited by this paper
• Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research

  2008cited by this paper
• Review of Nonprimate, Large Animal Models for Osteoporosis Research

  2008cited by this paper
• Key roles of the OPG–RANK–RANKL system in bone oncology

  2007cited by this paper
• Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?

  2007cited by this paper
• Structure-activity relationships of various bisphosphonates

  2006cited by this paper
• Remodeling dynamics in the alveolar process in skeletally mature dogs.

  2006cited by this paper
• Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment.

  2005cited by this paper
• Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.

  2005cited by this paper
• Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.

  2004cited by this paper
• Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma

  2003cited by this paper
• Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

  2003cited by this paper
• Bisphosphonate mechanism of action

  2002cited by this paper
• Cellular and molecular mechanisms of action of bisphosphonates

  2000cited by this paper
• Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.

  1991cited by this paper

• MEDICATION-RELATED OSTEONECROSIS OF THE JAW: A REVIEW STUDY

  2024cites this paper